Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling

Fig. 1

The expression of miR-378a-3p and miR-378d in serum exosomes is increased in breast cancer patients receiving chemotherapy and associated with chemoresistance. a Scanning electron microscopy of serum-exosomes isolated from patient serum. b Western blot analysis of the key enriched proteins CD81 and TSG101 in breast cancer patient serum exosomes. c Sequencing analysis of exosomal microRNAs from patient serum exosomes before receiving neoadjuvant chemotherapy, after receiving one cycle of neoadjuvant chemotherapy and after receiving four cycles of neoadjuvant chemotherapy. d Exosomes were isolated from the serum of breast cancer patients before and after neoadjuvant chemotherapy (n = 24). Variation in serum exosomal miR-378a-3p and miR-378d in groups with different responses to neoadjuvant chemotherapy. e Five-year survival rates in patients with low or high expression miR-378 based on the TCGA database (n = 854). f Analysis of miR-378 expression and the corresponding novel stemness index mRNAsi in 673 breast cancer patients in the TCGA database. g Pre- and post-chemotherapy expression data were analyzed by Gene set variation analysis for the breast cancer cohort (n = 10). h Western blot analysis of protein expression in breast cancer tissue before and after neoadjuvant chemotherapy in the no response group (n = 12). i The expression level of miR-378 was positively correlated with β-catenin, NOTCH1 or EZH2 in breast cancer (n = 470). *p < 0.05, ** p < 0.01, *** p < 0.001

Back to article page